NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$2.5b

Last Updated

2021/04/11 23:32 UTC

Data Sources

Company Financials +

Executive Summary

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. More Details


Snowflake Analysis

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Global Blood Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GBT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: GBT's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-4.3%

GBT

-2.2%

US Biotechs

2.1%

US Market


1 Year Return

-37.6%

GBT

31.5%

US Biotechs

56.3%

US Market

Return vs Industry: GBT underperformed the US Biotechs industry which returned 31.3% over the past year.

Return vs Market: GBT underperformed the US Market which returned 55.3% over the past year.


Shareholder returns

GBTIndustryMarket
7 Day-4.3%-2.2%2.1%
30 Day-7.4%-4.2%2.4%
90 Day-11.2%-5.5%6.1%
1 Year-37.6%-37.6%33.6%31.5%59.1%56.3%
3 Year-10.6%-10.6%26.9%21.1%65.7%55.1%
5 Year90.9%90.9%40.2%29.9%122.3%97.6%

Long-Term Price Volatility Vs. Market

How volatile is Global Blood Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Global Blood Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: GBT ($40.77) is trading below our estimate of fair value ($170.24)

Significantly Below Fair Value: GBT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: GBT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: GBT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GBT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GBT is overvalued based on its PB Ratio (6.1x) compared to the US Biotechs industry average (3.9x).


Future Growth

How is Global Blood Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

61.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GBT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: GBT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: GBT's is expected to become profitable in the next 3 years.

Revenue vs Market: GBT's revenue (38.5% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: GBT's revenue (38.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GBT's Return on Equity is forecast to be low in 3 years time (9.6%).


Past Performance

How has Global Blood Therapeutics performed over the past 5 years?

-32.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GBT is currently unprofitable.

Growing Profit Margin: GBT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GBT is unprofitable, and losses have increased over the past 5 years at a rate of 32.2% per year.

Accelerating Growth: Unable to compare GBT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GBT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).


Return on Equity

High ROE: GBT has a negative Return on Equity (-59.49%), as it is currently unprofitable.


Financial Health

How is Global Blood Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: GBT's short term assets ($632.2M) exceed its short term liabilities ($79.0M).

Long Term Liabilities: GBT's short term assets ($632.2M) exceed its long term liabilities ($228.8M).


Debt to Equity History and Analysis

Debt Level: GBT's debt to equity ratio (35.8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if GBT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GBT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if GBT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Global Blood Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GBT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GBT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GBT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GBT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GBT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

Ted Love (61 yo)

6.83yrs

Tenure

US$10,097,193

Compensation

Dr. Ted W. Love, M.D., serves as Independent Director at Royalty Pharma plc since July 30, 2020. He serves as Director of Seagen Inc. (formerly known as Seattle Genetics, Inc.). since August 2020. He serve...


CEO Compensation Analysis

Compensation vs Market: Ted's total compensation ($USD10.10M) is above average for companies of similar size in the US market ($USD5.05M).

Compensation vs Earnings: Ted's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: GBT's management team is considered experienced (4.5 years average tenure).


Board Members

Experienced Board: GBT's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.


Top Shareholders

Company Information

Global Blood Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Global Blood Therapeutics, Inc.
  • Ticker: GBT
  • Exchange: NasdaqGS
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.534b
  • Shares outstanding: 62.16m
  • Website: https://www.gbt.com

Number of Employees


Location

  • Global Blood Therapeutics, Inc.
  • 181 Oyster Point Boulevard
  • South San Francisco
  • California
  • 94080
  • United States

Listings


Biography

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an o...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 23:32
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.